Navigation Links
Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study

GOTHENBORG, Sweden, July 14 /PRNewswire/ -- PharmaSurgics AB. successfully completes Phase I clinical study showing their novel candidate drug PXL01 is safe and well tolerated. Initially developed to prevent post-surgical adhesion formation following hand surgery the product combines the pharmacological effect of PXL01 with the physical barrier effect of the vehicle, and has the potential to be the first anti-adhesion drug on the market. 'These results provide the foundation for proceeding to the next phase, proof of concept study in patients,' said Fredrik Sjovall, CEO of PharmaSurgics, adding 'the proof of concept study in patients of flexor tendon repair surgery is scheduled to start in December 2009.'

Post-surgical adhesions are bands of scar tissue connecting anatomic sites in the body that should not normally be connected. These develop after almost every type of surgery and cause symptoms such as restricted joint mobility, chronic pain, intestinal obstruction and re-operative complications. Following flexor tendon repair surgery post-surgical adhesions lead to decreased strength and function of the affected joints, extensive post-operative physiotherapy and extended periods of sick leave.

About PharmaSurgics

PharmaSurgics in Sweden AB is a Gothenburg based biotech company that develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. PharmaSurgics product concept is based on proprietary synthetic peptides which have strong anti-inflammatory and anti-infectious properties. The company was founded in 2005, based on extensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarker at Sahlgrenska University Hospital, Gothenborg, Sweden. PharmaSurgics is a Karolinska Development portfolio company.

    For further information please contact
    Fredrik Sjovall, CEO of PharmaSurgics
    Ph: +46-31-762-29-01

SOURCE PharmaSurgics AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EMcision Announces 510(k) Clearance of the Habib EndoHPB, its Novel Bipolar RF Device for the Palliation of Biliary and Pancreatic Tumours
2. Novel gene found for dilated cardiomyopathy
3. Novel drug discovery tool could identify promising new therapies for Parkinsons disease
4. Novel method predicts impact of a covert anthrax release
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Novel handheld device detects anthrax with outstanding accuracy and reliability
7. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
8. Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia
9. Clavis Pharma Raises NOK 129 Million (USD 20 Million) in a Private Placement to Fund Further Development of its Pipeline of Novel Anticancer Drug Candidates
10. Glenmarks Novel Molecule for Diabetes, Melogliptin to Enter Phase III Trials
11. Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model ... Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View ... years. Many AMA members have embraced this type of racing and several new model ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology:
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
(Date:10/27/2015)... 27, 2015 Munich, Germany ... Mapping technology (ASGM) automatically maps data from mobile eye ... , so that they can be quantitatively analyzed ... Munich, Germany , October 28-29, 2015. SMI,s ... from mobile eye tracking videos created with SMI,s ...
(Date:10/23/2015)... DUBLIN , Oct. 23, 2015 Research ... of the "Global Voice Recognition Biometrics Market 2015-2019" ... --> --> The global voice recognition ... during 2014-2019. --> ... 2015-2019, has been prepared based on an in-depth market ...
Breaking Biology News(10 mins):